Manifold Bio Strengthens Leadership Team with COO Appointment to Scale AI-Driven Drug Discovery Platform
核心洞察
Manifold Bio (搜索) appoints Paula Cobb (搜索) as Chief Operating Officer to drive operational scaling and business strategy for its AI-guided drug discovery platform.
The company's proprietary platform combines AI-guided protein design with massive-scale in vivo data generation to create tissue-targeted biologics across multiple therapeutic areas.
The leadership expansion follows Manifold Bio (搜索)'s successful partnership with Roche and positions the company to maximize its platform's potential for internal pipeline development and strategic collaborations.
Manifold Bio (搜索), a platform therapeutics company pioneering AI-guided drug discovery, has appointed Paula Cobb (搜索) as Chief Operating Officer to drive the scaling of its proprietary drug discovery engine. The appointment comes as the company advances its integrated platform that combines massive-scale in vivo data generation with AI-guided protein design to create tissue-targeted biologics.
Leadership Team Expansion
Ms. Cobb joins a leadership team anchored by Co-founders Gleb Kuznetsov (搜索) (CEO), Pierce Ogden (搜索) (CTO), and Shane Lofgren (搜索) (Head of Strategy). The executive bench was further strengthened earlier this year with the addition of Kimberly Scearce-Levie (搜索) as Chief Scientific Officer, alongside industry leaders Steve Holtzman (搜索) as Executive Chair and Doug Williams (搜索) as Chair of the Strategic Advisory Board.
"We have built a first-of-its-kind engine that combines the power of AI-guided antibody design with the physiological relevance of in vivo data, and we're expanding the team to drive our internal programs and advance a platform poised to address multiple therapeutic areas," said Gleb Kuznetsov (搜索), Ph.D., Co-founder and CEO of Manifold Bio (搜索).
Ms. Cobb brings extensive operational expertise from her previous role on the Board of Directors at Prothena Corporation (搜索), which she is stepping down from to focus on Manifold's operations. She has also held senior strategy and operations roles at Affinia Therapeutics (搜索), Decibel Therapeutics (搜索) and Biogen.
Platform Technology and Strategic Focus
Manifold Bio (搜索)'s proprietary drug discovery engine represents what the company describes as a first-of-its-kind platform that overcomes limitations of traditional discovery approaches. The platform enables precision protein engineering across diverse therapeutic areas by testing thousands of molecules simultaneously in vivo to uncover delivery strategies for tissue-targeted medicines.
"I'm thrilled to join Manifold Bio (搜索) at a moment when the industry is just beginning to realize what it means to truly unlock the full potential of AI with translationally relevant data generation," said Ms. Cobb. "The team has already built a powerful engine for discovering tissue-targeted protein therapeutics and secured a fantastic first deal with Roche."
The company's mDesign engine integrates AI-guided protein design with multiplexed in vivo data, creating what Manifold describes as a virtuous cycle of design and translation. This approach targets neurodegenerative, metabolic, and other major diseases where delivery and targeting challenges have historically plagued drug development.
Strategic Leadership Roles
The expanded leadership team brings specific expertise to different aspects of Manifold's growth strategy:
Paula Cobb (搜索), Chief Operating Officer: Will lead operational scaling and business strategy, translating the platform's technical success into corporate growth while focusing on internal pipeline development, advancing partnerships, and building operational foundations.
Steve Holtzman (搜索), Executive Chair: A veteran company builder focused on guiding corporate strategy to maximize the platform's full potential as a prolific engine for generating diverse therapeutic candidates and enabling strategic partnerships.
Kimberly Scearce-Levie (搜索), Ph.D., Chief Scientific Officer: Leads the translational application of the platform, bringing deep experience in drug discovery and development for neuroscience to apply high-throughput engineering capabilities to complex delivery and targeting challenges.
Doug Williams (搜索), Ph.D., Chair of Strategic Advisory: Provides decades of R&D leadership experience to help steer the company's long-term scientific roadmap and partnership strategies.
The leadership expansion positions Manifold Bio (搜索) to maximize what the company calls the "surface area" of its platform beyond any single therapeutic vertical, supporting both internal pipeline expansion and strategic collaborations with leading pharmaceutical partners worldwide.